Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Huntingtin Interacting Protein 1

  • Theodora S. Ross
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2867-3


HIP1 is the first example of an endocytic adapter protein that is altered in many human cancers. The following summary of HIP1’s role in cancer suggests that HIP1 represents a novel type of oncoprotein that hijacks endocytosis to increase signaling from multiple receptors in parallel to transform normal cells into cancer cells.



HIP1 is a 116 kDa cytosolic protein that was originally identified by yeast two hybrid screening for proteins that interact with huntingtin, the protein whose gene is mutated in Huntington’s disease. HIP1 and its only known mammalian relative, HIP1-related (HIP1r), contain clathrin-binding domains and carboxyl terminal actin-binding TALIN homology domains. HIP1 and HIP1r also contain amino terminal epsin/AP180 N-terminal homology (E/ANTH) domains. These domains bind specific inositol lipids and have been shown to be important in epsin- and AP180-mediated modulation of the growth factor receptor uptake phase of clathrin-mediated...


Epidermal Growth Factor Receptor Merkel Cell Carcinoma Membrane Trafficking Tramp Mouse Human HIP1 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Ames HM et al (2011) Huntingtin-interacting protein 1: a Merkel cell carcinoma marker that interacts with c-Kit. J Invest Dermatol 131(10):2113–2120CrossRefPubMedPubMedCentralGoogle Scholar
  2. Floyd S, De Camilli P (1998) Endocytosis proteins and cancer: a potential link? Trends Cell Biol 8:299–301CrossRefPubMedGoogle Scholar
  3. Hyun TS, Ross TS (2004) HIP1: trafficking roles and regulation of tumorigenesis. Trends Mol Med 10:194–199CrossRefPubMedGoogle Scholar
  4. Ou SH et al (2014/2015) Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol 9(12):1821–1825CrossRefPubMedGoogle Scholar
  5. Rao DS et al (2003) Altered receptor trafficking in huntingtin interacting protein 1-transformed cells. Cancer Cell 3:471–482CrossRefPubMedGoogle Scholar

See Also

  1. (2012) EGFR. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1211. doi: 10.1007/978-3-642-16483-5_1828Google Scholar
  2. (2012) Prognosis. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2994. doi: 10.1007/978-3-642-16483-5_4758Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity of Texas, Southwestern Medical CenterDallasUSA